10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-one

We are 10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-one CAS:59743-84-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-one
CAS.NO:   59743-84-9
Synonyms:
4-methoxybenzo[1,2]cyclohepta[3,4-b]thiophen-10-one

Molecular Formula: C14H10O2S
Molecular Weight:  242.29300

Physical and Chemical Properties:
Density: 1.32 g/cm3
Boiling point:436.4ºC at 760 mmHg
Melting point: 164-166℃
Flash point: 217.7±28.7 °C
Refractive index: 1.661

Specification:
Appearance:  Yellow powder
Purity:≥99.0%
Loss On Drying:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Storage:2°C-8°C.Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Intermediates of Ketotifen CAS:34580-13-7.

Related News: Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).[1- (etilsulfonil) azetidin-3-ilideno] acetonitrilo CAS:1187595-85-2 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).9'-fenil-9H, 9'H-2,3'-bicarbazol CAS:1345202-03-0 After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.367-86-2 After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.